Dec 17 2009
Cubist
Pharmaceuticals, Inc., (NASDAQ: CBST) a leading acute care
therapeutics company has completed its previously announced acquisition
of Calixa Therapeutics Inc., a biopharmaceutical company focused on the
development of novel antibiotics that address the expanding problem of
multi-drug resistant Gram-negative pathogens. Cubist’s agreement to
acquire Calixa was announced in a press
release issued on Dec. 14th, 2009.
Source:
Cubist Pharmaceuticals, Inc.
How viral persistence and immune dysfunction drive long COVID